Natalie S. Grover, MD

Natalie S. Grover, MD, assistant professor at the University of North Carolina Chapel Hill, discusses the potential role of CD30-specific chimeric antigen receptor (CAR) T cells in patients with relapsed/refractory Hodgkin lymphoma.

While the majority of patients treated in the first-line setting will do well, there is still a portion of patients that have refractory disease, Grover says. While there are great treatment options available, including brentuximab vedotin (Adcetris), and checkpoint inhibitors, these are still not curative.

Videos

Natalie S. Grover, MD, discusses the potential role of CD30-specific chimeric antigen receptor T cells in patients with relapsed/refractory Hodgkin Lymphoma.

Natalie S. Grover, MD | Authors

Articles

CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma